The hematologic oncology condition center is a comprehensive resource for clinical news and expert insights on hematologic oncology. Read more at OncLive.
May 1st 2024
Elias Jabbour, MD, discusses outcomes from the phase 3 PhALLCON trial in patients with Ph-positive acute lymphoblastic leukemia.
SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.
April 30th 2024
The investigational therapy IGNK001 has received orphan drug designation from the FDA for patients with acute myeloid leukemia.
April 29th 2024
Ibrahim Aldoss, MD, discusses the use of ponatinib as evaluated in the PhALLCON trial for patients with Ph+ ALL.
April 26th 2024
Kateryna Fedorov, MD, discusses considerations when deciding between quizartinib and midostaurin for patients with FLT3-mutated AML.
April 25th 2024
Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.
Annie Im, MD, FASCO, University of Pittsburgh/UPMC Hillman Cancer Center, discusses the various modern approaches for the treatment of patients with acute myeloid leukemia.
Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.
State of the Science Summit - Hematologic Malignancies: Chaired by Catherine E. Lai, MD, MPH
April 24th 2024
Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.
James Ignatz-Hoover, MD, PhD, discusses the implications of utilizing blinatumomab to treat acute lymphoblastic leukemia.
April 23rd 2024
State of the Science Summit - Hematology: Chaired by Martha Arellano, MD
Marc J. Braunstein, MD, PhD, FACP, of NYU Grossman Long Island School of Medicine, discusses lessons learned with program building and medical education with hematologic cancers.
April 22nd 2024
Catherine C. Coombs, MD, discusses the efficacy of the FLT3 inhibitor quizartinib in acute myeloid leukemia.
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
April 19th 2024
Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.
In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.
April 18th 2024
Catherine C. Coombs, MD, discusses strategies for disease classification and management for patients with acute myeloid leukemia.